A Single Blind, Randomised, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK206136 in Healthy Male Subjects and an Open Label Positron Emission Tomography Study to Evaluate the Serotonin Transporter and Neurokinin-1 Receptor Occupancy.
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
At a glance
- Drugs GSK 206136 (Primary)
- Indications Anxiety disorders; Depressive disorders
- Focus Adverse reactions; Pharmacokinetics
- 06 Feb 2010 New trial record